Short answer
McKesson Corporation (MCK) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Preliminary quarterly results for quarter ended September 30, 2026.
McKesson Corporation 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Preliminary quarterly results for quarter ended September 30, 2026
- Results available in Exhibit 99.1 for detailed financial metrics and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $111.0B, up 8%, with adjusted EPS $11.68, up 18%, signaling strong operating momentum
- Free cash flow $2.9B and $3.6B returned to shareholders year-to-date, including $3.4B in repurchases
- FY27 adjusted EPS guidance raised to $45.60-$46.40 from $44.20-$45.00, implying 17%-19% growth
- North American Pharmaceutical adjusted operating profit rose 22% to $1.0B, while Medical-Surgical Solutions declined 10% to $225M
- Planned $1.4B investment for approximately 49% of Option Care Health expands specialty-care exposure, pending approvals
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other McKesson Corporation 8-K filings
Get the next MCK 8-K as it lands
Follow MCK for push alerts, or ask the research agent what this filing means.